newsfilter
← Latest News
GlobeNewswire·

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

  • Caspian Therapeutics & Kura Oncology will host an investor webcast on Tuesday, October 13, 2026, at 4:30 p.m. ET.
  • Management will discuss the formation of Caspian & review KO-7246 data presented at the 62nd EASD Annual Meeting.
  • The live webcast & replay will be available on www.kuraoncology.com under the Investors tab.
  • Caspian Therapeutics focuses on menin-directed therapies for diabetes & cardiometabolic diseases using over a decade of research from Kura Oncology.
  • Caspian's lead compound, KO-7246, is an orally bioavailable menin inhibitor currently in IND-enabling development for a Phase 1 program to restore insulin production.
  • Caspian plans to advance a second development candidate for additional cardiometabolic indications.
  • Kura Oncology commercializes KOMZIFTI (ziftomenib), an FDA-approved menin inhibitor for NPM1-mutated acute myeloid leukemia.
  • Kura continues to pioneer advancements in menin inhibition & farnesyl transferase inhibition for hematologic malignancies & solid tumors.
  • Contact information is provided for Robert Spencer, Ph.D., at Caspian & Greg Mann at Kura Oncology.